Skip to content

Explore the changes of intestinal flora and metabolomics in patients with acute pancreatitis

Explore the changes of intestinal flora and metabolomics in patients with acute pancreatitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300078256
Enrollment
Unknown
Registered
2023-12-01
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute pancreatitis

Interventions

Biliary acute pancreatitis:NA
Hyperlipidemic acute pancreatitis:NA
Control group:NA

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
25 Years to 60 Years

Inclusion criteria

Inclusion criteria: Only patients who met the Revised Atlanta Classification (RAC) criteria were included in this study. The diagnosis of AP met two of the following three features: (1) abdominal pain consistent with acute pancreatitis (acute onset of a persistent, severe, epigastric pain often radiating to the back); (2) serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal; and (3) characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT) and less commonly magnetic resonance imaging (MRI) or transabdominal ultrasonography. Inclusion criteria for BAP met the following features: meeting the diagnostic criteria for AP; (4) gallbladder stones confirmed by ultrasound or MRCP. Inclusion criteria for HAP met the following features: meeting the diagnostic criteria for AP; (4) the level of triglyceride (TG) in serum reached or exceeded 11.3mmol/L; (5) excluding other causes, such as alcoholic, gallbladder, etc. and the TG was between 5.65-11.3mmol/L.

Exclusion criteria

Exclusion criteria: Subjects who meet any of the following criteria are not eligible for inclusion in this study. 1. Have used antibiotics, bismuth or PPI in the past 2 weeks; 2. Have used non-steroidal anti-inflammatory drugs in the past 4 weeks; 3. Severe heart, lung, brain, kidney, blood system, and endocrine system; 4. History of gastrointestinal surgery; 5.Suffering from malignant tumors or other systemic chronic diseases.

Design outcomes

Primary

MeasureTime frame
Fecal metabolome;Serum metabolome;Fecal flora;

Countries

China

Contacts

Public ContactLu Yingying

Shanghai General Hospital

yingying.lu1@shgh.cn+86 186 2158 3036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026